Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $104.00 to $117.00. They now have an "overweight" rating on the stock.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Piper Sandler from $140.00 to $115.00. They now have an "overweight" rating on the stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Ultragenyx to Participate at Investor Conferences in March